Surgical technology company Centese announced the successful closing of its $15M Series B round led by UCSF Rosenman Institute partner and affiliate, MedTech Venture Partners. The funding accelerates the Centese mission to transform the recovery process for heart and lung surgery patients, reducing complications, wasted resources, hospital stays, and unnecessary costs.
The UCSF Rosenman Institute has been a key partner and platform for MedTech Venture Partners by providing access to innovative technology through nationally acclaimed programs and a world-class investment and clinical advisory team. For its part, a return of the MedTech Venture Partners carried interest will be re-invested in the UCSF Rosenman Institute to support future funds, programs, and partnerships specifically designed for innovative start-up entrepreneurs.
From the press release:
OMAHA, Neb., November 21, 2023 (Newswire.com) – Centese, Inc., a leader in digital surgery technology, announces the successful closing of its $15M Series B funding round. The round, led by Medical Technology Venture Partners with participation from new and existing investors, will fund commercialization efforts, advance clinical initiatives, and bolster advanced product development of the Thoraguard Intelligent Chest Tube Management System.
“This Series B funding marks an exciting milestone for Centese,” said Evan Luxon, CEO of Centese, Inc. “This investment not only validates the rapid adoption of digital technology in surgery but will accelerate our mission to transform the recovery process for as many heart and lung surgery patients as possible.”
The Thoraguard System, recognized for its innovative solution to improve post-operative care in cardiac and thoracic surgery, has been validated in peer-reviewed clinical studies demonstrating superiority over legacy products. These studies, including those conducted at world-class institutions like Stanford University Medical Center and NYU Langone Health, have highlighted Thoraguard’s ability to shorten hospital stays, automate care, and provide superior monitoring of critical patient parameters.
In a strategic move to strengthen its leadership for this next phase, Centese, Inc. is also excited to announce the appointment of Timothy Still to its Board of Directors. Mr. Still, an accomplished CEO and Board Member, brings over three decades of experience leading organizations commercializing disruptive medical technologies in the areas of in vitro diagnostics, life science tools, medical devices, and digital health.
“Tim’s extensive experience and proven track record leading medtech organizations will be a tremendous asset as we transition Centese into our next phase of growth,” said Mr. Luxon. “His experience in commercial growth strategy, operational expansion, and M&A is well-aligned with our strategic goals.”
Mr. Still commented, “I am thrilled to join Centese at such a transformative time. The potential for the Thoraguard System to redefine post-operative care is enormous, and I look forward to contributing to the company’s growth and success.”